United States: FDA Finalizes Genetically Engineered Food Labeling Guidance & Approves "AquAdvantage Salmon"

Last Updated: November 26 2015
Article by Joanne S. Hawana

Last week will undoubtedly be marked in the annals of Food and Drug Administration history as an important milestone for the Agency. On November 19, 2015, FDA approved the first genetically engineered (GE) animal intended for use as human food – AquaBounty Technologies's AquAdvantage Salmon, a transgenic Atlantic salmon that contains a growth hormone gene from Chinook salmon that allows the fish to reach market size more quickly than traditional Atlantic salmon. The Agency's press release about the decision and related actions is available here.

FDA GE Labeling Guidance

At the same time that it announced the approval decision on AquAdvantage Salmon, FDA finalized its 2001 guidance document called "Voluntary Labeling Indicating Whether Foods Have or Have Not Been Derived from Genetically Engineered Plants" and also issued a new companion guidance in draft form that is specific to the voluntary labeling of foods derived from GE salmon. The main takeaway message from these documents is that the Agency's long-standing policy regarding labeling of foods containing genetically engineered ingredients has not changed, even after years of consumer and legislative pressure regarding the public's right to know whether a food contains one or more GE ingredients. In sum, when the food itself does not exhibit a "material" difference when it contains GE ingredients vs. non-GE counterparts, under existing law, FDA cannot make such labeling mandatory – however, voluntary statements about the method used to produce the food are acceptable as long as the food's label and labeling do not end up being false or misleading.

FDA's guidelines for such voluntary labeling provide basic principles to ensure that label statements are not false or misleading, along with examples of accurate statements that could be made either for foods that are not derived from GE plants or for foods that are. For example, the Agency explains that the term "GMO free" may be misleading on most foods because most foods don't contain any "organisms" and, moreover, the complete absence of any bioengineered ingredient may be difficult to substantiate. Expanding on that theme, the guidance documents also recommend ways to ensure that any voluntary labeling statements are substantiated.

AquAdvantage Salmon Approval

In addition, after reviewing information submitted in response to a specific request for comments on the labeling for GE salmon, the Agency did not find any data "showing that AquAdvantage Salmon is materially different from other Atlantic salmon in a manner that would require additional labeling." Thus, the new draft guidance document on this topic discusses ways in which voluntary label statements for the salmon may be made without running afoul of the prohibition on false or misleading representations for a food product.

The AquAdvantage Salmon approval was based on many years of data collection and regulatory review, with FDA's first involvement with the product coming in the mid-1990s. The inserted gene is regulated as a New Animal Drug because it is intended to "affect the structure or function" of the animal, so AquaBounty was required to demonstrate the safety and effectiveness of the drug, as well as the stability of the transgene in successive generations of the fish. Importantly, to mitigate any potential for environmental risks, the marketing approval includes the requirement for "multiple and redundant measures...to contain the fish and prevent their escape and establishment in the environment."

Specifically, they will only be bred and raised in land-based, contained hatchery tanks in two specific facilities in Canada and Panama (not in the U.S.), and FDA as well as the regulatory authorities in Canada and Panama will be inspecting those facilities to ensure their continued compliance with the various containment measures. Deviation from those measures will render the animal drug unsafe and adulterated, such that FDA would have authority to take enforcement action against the manufacturer even before any larger problems occur. The majority of the salmon also will be reproductively sterile and all-female to provide another layer of risk mitigation in the unlikely event of an escape.

Fallout from AquAdvantage Decision

The Agency clearly anticipated the criticism it would receive from environmental and consumer advocacy groups in response to the GE salmon decision, and it has emphasized that the fish are safe to eat and that the Agency essentially had no basis to reject the sponsor's application: "The fish are safe for humans and animals to eat, the rDNA construct is safe for the animal, and the claim about faster growth made by the sponsor has been confirmed. Because the sponsor has met these and other statutory requirements, the FDA must approve the application."

And, apparently seeking to be as transparent as possible in order to alleviate public concerns about the GE salmon and the first-ever GE animal intended for human food, FDA has prepared and released on its website numerous documents related to the regulatory action. Those AquAdvantage Salmon documents include the New Animal Drug approval letter; releasable summaries of the data and other materials reviewed; the environmental assessment and FONSI required to be prepared under the National Environmental Policy Act (NEPA) for any significant agency action; and a list of FAQs as well as a "fact sheet" that are more accessible to laypersons. The same page also provides links to documents stemming from a 2010 meeting of the Veterinary Medicine Advisory Committee in which the safety and effectiveness of the GE salmon was examined in depth.

Nonetheless, even after more than 20 years of data collection by the sponsor and many layers of active review by the Agency, opposition to the GE salmon is already intensifying. Senator Lisa Murkowski has introduced a bill, S. 738 or the "Genetically Engineered Salmon Risk Reduction Act," that would require labels of foods containing the fish to explicitly state that it contains GE salmon. And the Center for Food Safety immediately announced plans to sue the Agency along with other plaintiffs (such a challenge will likely be brought under the Administrative Procedure Act or NEPA, rather than the Federal Food, Drug, and Cosmetic Act, in light of the judicial deference afforded to agencies in interpreting and implementing their own rules). Not all consumer groups have decried the approval decision, however – for example, the Center for Science in the Public Interest issued a statement saying that it agreed with FDA's assessment that the salmon is safe to eat, is nutritionally equivalent to its non-GE counterpart, and will not harm the environment (and that it "may even be beneficial [to the environment] if AquaBounty's claims of efficiency are realized").

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Jones Day
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Jones Day
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions